Home Tags SWOG S0106

Tag: SWOG S0106

From Withdrawal to Reapproval – Lessons From Gemtuzumab ozogamicin and Belantamab...

Peter Hofland
Two FDA-approved antibody-drug conjugates (ADCs)—gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth) and belantamab mafodotin (Blenrep®; GSK)—were withdrawn from the U.S. market after confirmatory trials failed to verify...